{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:25:36Z","timestamp":1787797536865,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.pan.2022.06.009","type":"journal-article","created":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T13:34:07Z","timestamp":1655040847000},"page":"741-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8882-2348","authenticated-orcid":false,"given":"Benjamin E.","family":"Ueberroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios S.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2022.06.009_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s002689900215","article-title":"Recurrence after resection for ductal adenocarcinoma of the pancreas","volume":"21","author":"Sperti","year":"1997","journal-title":"World J Surg"},{"key":"10.1016\/j.pan.2022.06.009_bib2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s12885-018-4610-4","article-title":"Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a seer-based study","volume":"18","author":"Saad","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","article-title":"8th edition of the ajcc cancer staging manual: pancreas and hepatobiliary cancers","volume":"25","author":"Chun","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib4","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1158\/1078-0432.CCR-19-3685","article-title":"Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer","volume":"26","author":"Axelrod","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2018.09.022","article-title":"Detection of minimal residual disease using ctdna in lung cancer: current evidence and future directions","volume":"14","author":"Chae","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.9032","article-title":"Circulating tumor DNA-defined minimal residual disease in solid tumors: opportunities to accelerate the development of adjuvant therapies","author":"Dasari","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage ii colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pan.2022.06.009_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091399","article-title":"Matched whole-genome sequencing (wgs) and whole-exome sequencing (wes) of tumor tissue with circulating tumor DNA (ctdna) analysis: complementary modalities in clinical practice","volume":"11","author":"Imperial","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.pan.2022.06.009_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1634\/theoncologist.2017-0467","article-title":"Mutant kras circulating tumor DNA is an accurate tool for pancreatic cancer monitoring","volume":"23","author":"Perets","year":"2018","journal-title":"Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/1878-0261.12978","article-title":"Detection and relevance of epigenetic markers on ctdna: Recent advances and future outlook","volume":"15","author":"Lianidou","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/1878-0261.12827","article-title":"Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA","volume":"15","author":"Bos","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib14","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1158\/1078-0432.CCR-21-0417","article-title":"Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA","volume":"27","author":"Chen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12916-018-1157-9","article-title":"Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection","volume":"16","author":"Fiala","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.pan.2022.06.009_bib16","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/1078-0432.CCR-13-0606","article-title":"Pik3ca, braf, and pten status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from ncic ctg\/agitg co.17","volume":"20","author":"Karapetis","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib17","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2022.06.009_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004271","article-title":"Changes in colorectal carcinoma genomes under anti-egfr therapy identified by whole-genome plasma DNA sequencing","volume":"10","author":"Mohan","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.pan.2022.06.009_bib19","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-19-0197","article-title":"Circulating tumor DNA as a clinical test in resected pancreatic cancer","volume":"25","author":"Groot","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12885-020-07736-x","article-title":"Longitudinal analysis of cell-free mutated kras and ca 19-9 predicts survival following curative resection of pancreatic cancer","volume":"21","author":"Hussung","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1373\/clinchem.2017.283721","article-title":"Prognostic implications of multiplex detection of kras mutations in cell-free DNA from patients with pancreatic ductal adenocarcinoma","volume":"64","author":"Kim","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.pan.2022.06.009_bib22","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","article-title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1078-0432.CCR-16-0806","article-title":"Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker","volume":"23","author":"Pietrasz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib24","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1245\/s10434-020-09278-9","article-title":"Clinical implications of pre- and postoperative circulating tumor DNA in patients with resected pancreatic ductal adenocarcinoma","volume":"28","author":"Yamaguchi","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib25","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.tranon.2018.07.013","article-title":"Measuring kras mutations in circulating tumor DNA by droplet digital pcr and next-generation sequencing","volume":"11","author":"Demuth","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib26","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1373\/clinchem.2019.305805","article-title":"Comparison of beaming and droplet digital pcr for circulating tumor DNA analysis","volume":"65","author":"O'Leary","year":"2019","journal-title":"Clin Chem"},{"key":"10.1016\/j.pan.2022.06.009_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02825415","article-title":"K-ras mutation and pancreatic adenocarcinoma","volume":"18","author":"Caldas","year":"1995","journal-title":"Int J Pancreatol"},{"key":"10.1016\/j.pan.2022.06.009_bib28","first-page":"9","article-title":"Braf mutation in colorectal cancer: an update","volume":"7","author":"Barras","year":"2015","journal-title":"Biomarkers Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib29","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.prp.2009.07.010","article-title":"Frequency and type of kras mutations in routine diagnostic analysis of metastatic colorectal cancer","volume":"205","author":"Neumann","year":"2009","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.pan.2022.06.009_bib30","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/cncr.29364","article-title":"Detection of k-ras gene mutation by liquid biopsy in patients with pancreatic cancer","volume":"121","author":"Kinugasa","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00535-003-1245-1","article-title":"Detection of k-ras mutations in the plasma DNA of pancreatic cancer patients","volume":"39","author":"Uemura","year":"2004","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.pan.2022.06.009_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pan.2022.06.009_bib33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ijc.30798","article-title":"Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma","volume":"141","author":"Cai","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib34","first-page":"14","article-title":"Postoperative circulating tumor DNA as markers of recurrence risk in stages ii to iii colorectal cancer","author":"Chen","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.pan.2022.06.009_bib36","first-page":"10","article-title":"Circulating tumor DNA as a potential marker to detect minimal residual disease and predict recurrence in pancreatic cancer","author":"Jiang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bjc.2016.175","article-title":"Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer","volume":"115","author":"Hadano","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MPA.0000000000001730","article-title":"Circulating cell-free DNA in pancreatic head adenocarcinoma undergoing pancreaticoduodenectomy","volume":"50","author":"Wang","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2022.06.009_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227366","article-title":"Longitudinal monitoring of kras-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer","volume":"14","author":"Watanabe","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.pan.2022.06.009_bib40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/bjc.2017.479","article-title":"Kras mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study","volume":"118","author":"Nakano","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12885-021-08031-z","volume":"21","author":"Janssen","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/s12885-017-3441-z","article-title":"Alliance for clinical trials in oncology (alliance) trial a021501: preoperative extended chemotherapy vs. Chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas","volume":"17","author":"Katz","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2022.06.009_bib43","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/annonc\/mdy417","article-title":"Repeated (mut)kras ctdna measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer","volume":"29","author":"Kruger","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2022.06.009_bib44","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1158\/1078-0432.CCR-20-0950","article-title":"Circulating tumor DNA is prognostic and potentially predictive of eryaspase efficacy in second-line in patients with advanced pancreatic adenocarcinoma","volume":"26","author":"Bachet","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical outcome results from swog s1505: a randomized clinical trial of mfolfirinox versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2022.06.009_bib46","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the compass trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/bjc.2015.328","article-title":"Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after folfirinox failure: an ageo prospective multicentre cohort","volume":"113","author":"Portal","year":"2015","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.pan.2022.06.009_bib48","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib49","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1158\/1078-0432.CCR-17-0510","article-title":"Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer","volume":"23","author":"Scholer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2022.06.009_bib50","first-page":"4365","article-title":"Monitoring colorectal cancer following surgery using plasma circulating tumor DNA","volume":"15","author":"Sun","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pan.2022.06.009_bib51","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/cam4.3755","article-title":"Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer","volume":"10","author":"Ko","year":"2021","journal-title":"Cancer Med-Us"},{"key":"10.1016\/j.pan.2022.06.009_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0040-1716333","article-title":"Targeted sequencing analysis of matched cell-free DNA and white blood cells: a facile method for detection of residual disease in gastric cancer","volume":"7","author":"Diao","year":"2020","journal-title":"Glob Med Genet"},{"key":"10.1016\/j.pan.2022.06.009_bib53","first-page":"11","article-title":"White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer","author":"Leal","year":"2020","journal-title":"Nat Commun"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390322002046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390322002046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T15:27:21Z","timestamp":1662737241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390322002046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1424390322002046"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2022.06.009","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2022.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}